Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback